Cargando…
Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome
We investigated the effects of gut microbiota and serum metabolite levels in patients with Budd-Chiari syndrome (B-CS) and their importance for guiding clinical management strategies. In total, 214 B-CS patients (93 untreated and 121 treated) and 41 healthy controls were enrolled. Gut microbiota and...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567795/ https://www.ncbi.nlm.nih.gov/pubmed/34746022 http://dx.doi.org/10.3389/fcimb.2021.730091 |
_version_ | 1784594303985647616 |
---|---|
author | Lu, Qinwei Xu, Hao Zhou, Lin Zhang, Ruifang Li, Zhen Xu, Peng Bai, Tao Wang, Zhiwei Wu, Gang Ren, Jianzhuang Jiao, Dechao Song, Yan Zhu, Rongtao Li, Jian Wang, Weijie Liang, Ruopeng Li, Lin Ma, Xiuxian Zu, Maoheng Sun, Yuling |
author_facet | Lu, Qinwei Xu, Hao Zhou, Lin Zhang, Ruifang Li, Zhen Xu, Peng Bai, Tao Wang, Zhiwei Wu, Gang Ren, Jianzhuang Jiao, Dechao Song, Yan Zhu, Rongtao Li, Jian Wang, Weijie Liang, Ruopeng Li, Lin Ma, Xiuxian Zu, Maoheng Sun, Yuling |
author_sort | Lu, Qinwei |
collection | PubMed |
description | We investigated the effects of gut microbiota and serum metabolite levels in patients with Budd-Chiari syndrome (B-CS) and their importance for guiding clinical management strategies. In total, 214 B-CS patients (93 untreated and 121 treated) and 41 healthy controls were enrolled. Gut microbiota and serum metabolome were analysed using shotgun metagenomics and liquid chromatography-mass spectrometry. The gut microbiota of the patients showed abundance of Campylobacter and low levels of Saccharomyces, Deinococcus, and Thiomonas (P < 0.05). Thirty metabolites, including taurocholate and (R)-3-hydroxybutyric acid, were identified in the patients (VIP > 1, P < 0.05 and FC > 1.2 or FC < 0.83). Random forest (RF) models showed that serum metabolome could effectively identify B-CS from healthy controls and RF-metabolomics exhibited perfect discrimination (AUC = 100%, 95% CI: 100% – 100%), which was significantly higher than that achieved by RF-metagenomics (AUC = 58.48%, 95% CI: 38.46% – 78.5%). Campylobacter concisus and taurocholate showed significant positive correlation in patients with clinical manifestations (P < 0.05). Actinobacteria levels were significantly higher in untreated patients than in treated patients (P < 0.05). Campylobacter and Veillonella levels were significantly higher in treated patients than in healthy controls (P < 0.05). We identified major alterations in the gut microbiota and serum metabolome of patients with B-CS. Faecal metagenomics- and serum metabolomics-guided management strategies are required for patients with B-CS. |
format | Online Article Text |
id | pubmed-8567795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85677952021-11-05 Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome Lu, Qinwei Xu, Hao Zhou, Lin Zhang, Ruifang Li, Zhen Xu, Peng Bai, Tao Wang, Zhiwei Wu, Gang Ren, Jianzhuang Jiao, Dechao Song, Yan Zhu, Rongtao Li, Jian Wang, Weijie Liang, Ruopeng Li, Lin Ma, Xiuxian Zu, Maoheng Sun, Yuling Front Cell Infect Microbiol Cellular and Infection Microbiology We investigated the effects of gut microbiota and serum metabolite levels in patients with Budd-Chiari syndrome (B-CS) and their importance for guiding clinical management strategies. In total, 214 B-CS patients (93 untreated and 121 treated) and 41 healthy controls were enrolled. Gut microbiota and serum metabolome were analysed using shotgun metagenomics and liquid chromatography-mass spectrometry. The gut microbiota of the patients showed abundance of Campylobacter and low levels of Saccharomyces, Deinococcus, and Thiomonas (P < 0.05). Thirty metabolites, including taurocholate and (R)-3-hydroxybutyric acid, were identified in the patients (VIP > 1, P < 0.05 and FC > 1.2 or FC < 0.83). Random forest (RF) models showed that serum metabolome could effectively identify B-CS from healthy controls and RF-metabolomics exhibited perfect discrimination (AUC = 100%, 95% CI: 100% – 100%), which was significantly higher than that achieved by RF-metagenomics (AUC = 58.48%, 95% CI: 38.46% – 78.5%). Campylobacter concisus and taurocholate showed significant positive correlation in patients with clinical manifestations (P < 0.05). Actinobacteria levels were significantly higher in untreated patients than in treated patients (P < 0.05). Campylobacter and Veillonella levels were significantly higher in treated patients than in healthy controls (P < 0.05). We identified major alterations in the gut microbiota and serum metabolome of patients with B-CS. Faecal metagenomics- and serum metabolomics-guided management strategies are required for patients with B-CS. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8567795/ /pubmed/34746022 http://dx.doi.org/10.3389/fcimb.2021.730091 Text en Copyright © 2021 Lu, Xu, Zhou, Zhang, Li, Xu, Bai, Wang, Wu, Ren, Jiao, Song, Zhu, Li, Wang, Liang, Li, Ma, Zu and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Lu, Qinwei Xu, Hao Zhou, Lin Zhang, Ruifang Li, Zhen Xu, Peng Bai, Tao Wang, Zhiwei Wu, Gang Ren, Jianzhuang Jiao, Dechao Song, Yan Zhu, Rongtao Li, Jian Wang, Weijie Liang, Ruopeng Li, Lin Ma, Xiuxian Zu, Maoheng Sun, Yuling Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
title | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
title_full | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
title_fullStr | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
title_full_unstemmed | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
title_short | Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome |
title_sort | alterations in faecal metagenomics and serum metabolomics indicate management strategies for patients with budd-chiari syndrome |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567795/ https://www.ncbi.nlm.nih.gov/pubmed/34746022 http://dx.doi.org/10.3389/fcimb.2021.730091 |
work_keys_str_mv | AT luqinwei alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT xuhao alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT zhoulin alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT zhangruifang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT lizhen alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT xupeng alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT baitao alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT wangzhiwei alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT wugang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT renjianzhuang alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT jiaodechao alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT songyan alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT zhurongtao alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT lijian alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT wangweijie alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT liangruopeng alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT lilin alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT maxiuxian alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT zumaoheng alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome AT sunyuling alterationsinfaecalmetagenomicsandserummetabolomicsindicatemanagementstrategiesforpatientswithbuddchiarisyndrome |